DE3219004C1 - Pharmaceutical compositions for the treatment of tumours - Google Patents
Pharmaceutical compositions for the treatment of tumoursInfo
- Publication number
- DE3219004C1 DE3219004C1 DE19823219004 DE3219004A DE3219004C1 DE 3219004 C1 DE3219004 C1 DE 3219004C1 DE 19823219004 DE19823219004 DE 19823219004 DE 3219004 A DE3219004 A DE 3219004A DE 3219004 C1 DE3219004 C1 DE 3219004C1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- pharmaceutical compositions
- tumours
- dodecafluoro
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title description 4
- 239000003814 drug Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- BYKNGMLDSIEFFG-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoroheptan-1-ol Chemical compound OCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)F BYKNGMLDSIEFFG-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010049438 General physical health deterioration Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000030394 cerebellar neoplasm Diseases 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Gegenstand der Erfindung sind Arzneimittel zur Behandlung von Tumoren, insbesondere von malignen Tumoren, dieThe invention relates to medicaments for the treatment of tumors, in particular malignant ones Tumors that
1 H1I H,7 H-Dodecafluor-1-heptanol1 H 1 IH, 7 H -dodecafluoro-1-heptanol
als Wirkstoff enthalten.contained as an active ingredient.
Die Erfindung beruht auf der überraschenden Feststellung, daßThe invention is based on the surprising finding that
1 H.l H.7 H-Dodecafluor-1-heptanol1 H.l H.7 H-dodecafluoro-1-heptanol
wertvolle krebshemmende Eigenschaften hat.has valuable anti-cancer properties.
Das erfindungsgemäße Arzneimittel ist beispielsweise äußerst wirksam bei der Behandlung und Bekämpfung'von Gehirntumoren und Ovarialcarcinomen.The medicament according to the invention is, for example, extremely effective in the treatment and control of Brain tumors and ovarian carcinomas.
Das in den erfindungsgemäßen Arzneimitteln enthaltene 1 H1I H.7 H-Dodecafluor-1-heptanol ist bekannt. Es ist bei Raumtemperatur flüssig. Es kann unverdünnt oder mit üblichen pharmakologisch verträglichen Träger- und/oder Verdünnungsmitteln verdünnt in Form von Tropfen. Injektionslösungen oder in Kapseln abgefüllt verabreicht werden. The 1 H 1 I H.7 H-dodecafluoro-1-heptanol contained in the medicaments according to the invention is known. It is liquid at room temperature. It can be used undiluted or diluted with customary pharmacologically acceptable carriers and / or diluents in the form of drops. Injection solutions or filled into capsules can be administered.
Die Wirkungsweise des erfindungsgemäßen Arzneimittels wird an den nachfolgenden Krankengeschichten veranschaulicht:The mode of action of the medicament according to the invention is illustrated in the following case histories illustrates:
Krankengeschichte I (nachgereicht)Medical history I (submitted later)
Ein 1970 geborenes Mädchen wurde 1978 an einem Kleinhirntumor operiert. 1981 wurden zwei neue Tumorknoten festgestellt. Das Befinden der Patientin verschlechterte sich Ende August 1981 erheblich. Es traten Lähmungserscheinungen an Armen und Beinen sowie Sprachstörungen auf. Eine nochmalige Behand-A girl born in 1970 was operated on for a cerebellar tumor in 1978. In 1981 two new tumor nodules were found. The patient's condition deteriorated considerably at the end of August 1981. There were symptoms of paralysis in the arms and legs as well as speech disorders. Another treatment
lung wurde von den damals behandelnden Ärzten abgelehnt.treatment was rejected by the doctors treating it at the time.
Die Patientin wurde unter ausdrücklicher Einwilligung der Eltern in der Zeit vom 06.09.1981 bis 09.10 1981 mit 1 H.1 H,7 H-Dodecafluor-1-heptanol inWith the express consent of the parents, the patient was born in the period from 09/06/1981 to October 9, 1981 with 1 H.1 H, 7 H-dodecafluoro-1-heptanol in
tu einer täglichen Dosis von 0,05 ml stationär behandelt. Wegen des reduzierten Allgemeinzustandes bekam die Patientin begleitend Schonkost sowie Vitaminpräparate. Anschließend erfolgte eine ambulante Nachbehandlung bis zum 25. März 1982 in gleicher Dosierung, sodann einen weiteren Monat mit halber Dosierung.do a daily dose of 0.05 ml. Because of the reduced general condition, the patient was given light food and vitamin supplements. This was followed by outpatient follow-up treatment until March 25, 1982 in the same dosage, then another month at half the dosage.
Innerhalb von kurzer Zeit verbesserte sich der Zustand der Patientin erstaunlich, so daß sie am 9. Oktober 198 t nach Hause entlassen werden konnte. Sie konnte damals bereits wieder die Schule besuchen.Within a short period of time, the patient's condition improved astonishingly, so that she was am October 9, 198 t could be released home. At that time she was able to go to school again.
Mitte 1982 ergab eine Computer-Tomographie, daß die vor der Behandlung festgestellten Metastasen nicht mehr nachweisbar waren.In mid-1982, a computed tomography showed that the metastases found before treatment were not were more detectable.
Krankengeschichte Il (nachgereicht)Medical history II (submitted later)
Eine 1923 geborene Frau litt an einem Ovarialcarcinom im Endstadium mit weitgehender Metastasierung. Am 19.06.1978 wurde eine Radikaloperation des Uterus mit Adnexen und Ovarien vorgenommen. Da die Metastasierung operativ nicht behandclbar war. erfolg-A woman born in 1923 suffered from terminal ovarian carcinoma with extensive metastasis. On June 19, 1978 a radical operation of the uterus with adnexa and ovaries was performed. Since the Metastasis could not be treated surgically. success-
jo te mit dem Einverständnis der Patientin eine postoperative Nachbehandlung mit 1 H1I H,7 H-Dodecafluor-1-hcptanol in einer täglichen Dosis von 0.1 ml. Die Behandlung erfolgte bis 19.08.1978 stationär. Anschließend wurde die Patientin nach Hause entlassen und abWith the consent of the patient, a postoperative follow-up treatment with 1 H 1 IH, 7 H-dodecafluoro-1-hcptanol in a daily dose of 0.1 ml. The treatment was inpatient until August 19, 1978. The patient was then discharged home and off
3". 30.09.1978 wieder arbeitsfähig geschrieben. In den Jahren 1979 und 1980 wurde kein carcinogener Befund mehr festgestellt. Die Frau befindet sich gegenwärtig in gutem Allgemeinzustand und ist arbeitsfähig.3 ". 30.09.1978 written able to work again. In the In 1979 and 1980 no more carcinogenic findings were found. The woman is currently in good general condition and is able to work.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19823219004 DE3219004C1 (en) | 1982-05-19 | 1982-05-19 | Pharmaceutical compositions for the treatment of tumours |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19823219004 DE3219004C1 (en) | 1982-05-19 | 1982-05-19 | Pharmaceutical compositions for the treatment of tumours |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3219004C1 true DE3219004C1 (en) | 1984-03-01 |
Family
ID=6164095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19823219004 Expired DE3219004C1 (en) | 1982-05-19 | 1982-05-19 | Pharmaceutical compositions for the treatment of tumours |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3219004C1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3319304A1 (en) * | 1982-05-28 | 1983-12-01 | Alphatime Ltd. Co. Inc., Berkhamsted, Hertfordshire | MEDICINAL PRODUCTS WITH ANTINEOPLASTIC EFFECT |
| EP0452941A3 (en) * | 1990-04-19 | 1992-09-09 | Dai-Ichi Kogyo Seiyaku Co., Ltd. | Use of isomonools in the treatment and prophylaxis of cancer |
| WO2006036083A1 (en) * | 2004-09-09 | 2006-04-06 | Obschestvo S Ogranichennoi Otvetstvennostyu 'proektno- Konstruktorskoe I Proizvodstvenno- Vnedrencheskoe Predpriyatie 'deimos Ltd' | Extraction of radionuclides by crown ether-containing extractants |
-
1982
- 1982-05-19 DE DE19823219004 patent/DE3219004C1/en not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| CA, Vol. 94, 1981, 41866w * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3319304A1 (en) * | 1982-05-28 | 1983-12-01 | Alphatime Ltd. Co. Inc., Berkhamsted, Hertfordshire | MEDICINAL PRODUCTS WITH ANTINEOPLASTIC EFFECT |
| FR2527439A1 (en) * | 1982-05-28 | 1983-12-02 | Fcn Srl | PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE POLYFLUORINE ALCOHOL |
| EP0452941A3 (en) * | 1990-04-19 | 1992-09-09 | Dai-Ichi Kogyo Seiyaku Co., Ltd. | Use of isomonools in the treatment and prophylaxis of cancer |
| WO2006036083A1 (en) * | 2004-09-09 | 2006-04-06 | Obschestvo S Ogranichennoi Otvetstvennostyu 'proektno- Konstruktorskoe I Proizvodstvenno- Vnedrencheskoe Predpriyatie 'deimos Ltd' | Extraction of radionuclides by crown ether-containing extractants |
| JP2008512675A (en) * | 2004-09-09 | 2008-04-24 | オブシェストボ エス オグラニチェンノイ オトベツトベンノスチュ“プロエクトノ−コンストルクトルスコエ イー プロイズボヅトベンノ−ブネドレンチェスコエ プレドプリヤティエ“デイモス リミティド” | Extraction of radionuclides using extractants containing crown ether |
| US7927566B2 (en) | 2004-09-09 | 2011-04-19 | Designing-Contructing and Industrial-Inculcating Enterprise “Daymos Ltd.” | Extraction of radionuclides by crown ether-containing extractants |
| CN101019194B (en) * | 2004-09-09 | 2012-10-10 | 迪姆斯设计建筑和工业创新有限责任公司 | Extraction of radionuclides by crown ether-containing extractants |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2332484A1 (en) | DELAYED RELEASE LUGGAGE PASTRIES | |
| DE3219004C1 (en) | Pharmaceutical compositions for the treatment of tumours | |
| DE3818022C2 (en) | Soft gelatin capsule | |
| DE19716660C2 (en) | Preparations, in particular pharmaceutical and pharmaceutical forms based on plants, for combating Helicobacter pylori infections | |
| DE3918543C2 (en) | ||
| DE2451933C2 (en) | ||
| DE2625220C3 (en) | Medicines used to treat liver disease | |
| DE1941942A1 (en) | New pharmaceutical agent | |
| DE4335441A1 (en) | Preventive medical composition for the human cardiovascular system | |
| DE2015877A1 (en) | drug | |
| DE10238161A1 (en) | Mucosal or topical administration of minerals, e.g. for treating muscle spasms, psoriasis or osteoporosis or promoting wound healing, comprises direct application of mineral solution from ampoule | |
| DE3801900A1 (en) | Use of terpene-containing essential oils for controlling Aids and Arc, and pharmaceutical compositions containing them | |
| DE2441621A1 (en) | Cysteine-contg ophthalmic preparations - in the form of an oxygen-free polyacrylic acid gel | |
| DE3638290A1 (en) | Pharmaceutical composition | |
| DE2334358A1 (en) | PHARMACEUTICAL PREPARATIONS WITH A NEW EFFECT | |
| DE2004281C3 (en) | Vasodilator agent | |
| US3562388A (en) | Treatment for mammals infected with pathogenic bacteria | |
| US2221690A (en) | Therapeutic composition | |
| CN120936379A (en) | Homeopathic blends for relieving general fatigue symptoms and fatigue symptoms related to cancer treatment. | |
| US2021044A (en) | Castor oil preparation | |
| Steigmann et al. | Acidity modification therapy in peptic ulcer | |
| EP0388695A1 (en) | Preparation and its use | |
| DE3331459A1 (en) | Composition for tumour treatment containing diazoxide, and the use thereof | |
| DE3242796A1 (en) | MEDICINAL PRODUCTS FOR THE TREATMENT OF DISEASES OF THE BREATHING ORGANS | |
| DE3239592C2 (en) | Antibacterial drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8100 | Publication of the examined application without publication of unexamined application | ||
| D1 | Grant (no unexamined application published) patent law 81 | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |